logo
Mangoceuticals shares results from field studies on MGX-0024

Mangoceuticals shares results from field studies on MGX-0024

Yahoo28-05-2025
Mangoceuticals (MGRX) shares results from field studies based on its patented antiviral compound which it refers to as 'MGX-0024'. The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease, CRD, showed MGX-0024, delivered through drinking water, achieved 100% survival against respiratory illnesses in a large-scale trial, offering a promising solution for poultry health and avian flu defense. In the first study, 8,000 chickens starting at 25 days old received MGX-0024-infused water, resulting in about 50 deaths per day from respiratory diseases, compared to 200 per day on a neighboring untreated farm using the same chick batch. The farm noted that some deaths may have been due to pre-infected chickens too weak to drink the treated water. In a second study, 10,000 chicks treated from 7 days old, for 48 days, with no other antibacterial or antiviral feed additives administered, had no deaths from respiratory diseases, despite an expected 50% mortality rate based on a nearby farm's losses. Only 20 chickens died due to unrelated heat exposure. MGX-0024, a blend of natural polyphenols and zinc, Generally Recognized as Safe ingredients, is also under evaluation for use in preventing avian flu in a lab study with Vipragen Biosciences and an Indian government laboratory, with results expected soon.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MGRX:
Disclaimer & DisclosureReport an Issue
Mangoceuticals, Inc. Terminates Agreements with Key Partners
Mangoceuticals Settles Lawsuit with Stock Issuance
Mangoceuticals Acquires IP to Expand Product Line
Mangoceuticals enters into agreement to acquire assets of Smokeless Technology
Mangoceuticals Issues Bonus Shares to Leadership
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amazon (AMZN) Gets a Buy from Telsey Advisory
Amazon (AMZN) Gets a Buy from Telsey Advisory

Business Insider

timean hour ago

  • Business Insider

Amazon (AMZN) Gets a Buy from Telsey Advisory

In a report released today, Jason Strominger from Telsey Advisory maintained a Buy rating on Amazon, with a price target of $265.00. The company's shares closed yesterday at $211.65. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Strominger is a 2-star analyst with an average return of 1.7% and a 57.14% success rate. Strominger covers the Consumer Cyclical sector, focusing on stocks such as Lululemon Athletica, Ralph Lauren, and Ulta Beauty. In addition to Telsey Advisory, Amazon also received a Buy from Citi's Ronald Josey in a report issued yesterday. However, on August 1, Wells Fargo reiterated a Hold rating on Amazon (NASDAQ: AMZN).

OpenAI Hits 700 Million Users, $300 Billion Valuation as $8 Billion Cash Burn Is Projected
OpenAI Hits 700 Million Users, $300 Billion Valuation as $8 Billion Cash Burn Is Projected

Business Insider

time4 hours ago

  • Business Insider

OpenAI Hits 700 Million Users, $300 Billion Valuation as $8 Billion Cash Burn Is Projected

OpenAI is set to hit a major user milestone, reaching 700 million weekly active users. That is up 40% from 500 million at the end of March and about four times the number from the same period last year. The company says it now handles about 2.5 billion prompts each day from around 330 million individual users. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The growth comes alongside a large funding boost. OpenAI recently completed an $8.3 billion funding round at a $300 billion valuation, months ahead of schedule. The round was led by Dragoneer Investment Group, which invested $2.8 billion. Other new investors include Blackstone, TPG, and T. Rowe Price, while Andreessen Horowitz and Sequoia Capital returned. This raise is part of OpenAI's plan to secure $40 billion in 2025. The company raised $2.5 billion in March. OpenAI's annualized revenue is about $13 billion and could reach $20 billion by the end of the year if current trends hold. The funding is expected to support product development and expand its reach into more business and consumer markets. Growth Is Evident, But Costs and Competition Mount Feature updates are also playing a role in the growth. The ChatGPT Projects tool has been expanded with more research features, voice mode, and a memory system that can recall past conversations inside projects. These changes are making it easier for users to manage longer and more complex work inside the platform. OpenAI now counts more than 5 million paying business subscribers, up from 3 million in June. However, the company faces financial and competitive challenges as it expects to burn about $8 billion in cash by the end of 2025. Current projections suggest it will not reach cash-flow breakeven before 2029. Also, competition from Google DeepMind (GOOG), Meta (META), and Microsoft (MSFT) -backed AI projects is also increasing. Moreover, China-based companies are also threatening American companies' AI dominance, such as Alibaba's (BABA) Qwen 3, and DeepSeek's R1 model. In short, OpenAI's combination of rapid user growth, higher revenue, and heavy investment is impressive and even formidable. Still, retail investors will be watching to see if the company can sustain this pace while managing costs and defending its position in a fast-growing market. Using TipRanks' Comparison Tool, we've compared some of the notable companies that employ ChatGPT similar to OpenAI's ChatGPT.

Stock Market Today: Algorithms Are Not Efficient
Stock Market Today: Algorithms Are Not Efficient

Miami Herald

time7 hours ago

  • Miami Herald

Stock Market Today: Algorithms Are Not Efficient

I began my career not in journalism but on the New York Stock Exchange. Technically, I wasn't on the floor, but I worked 16 stories above it, trading through a network of brokers who were on the floor. I was there in trading activity, if not in body. It probably shows in my writing. Back in those days some 1,300 traders plus support staff made up the crowds where stocks were traded and prices were discovered. It was a loud and active place, where price efficiency ruled. Today, the NYSE floor is an empty place. Market makers still work there, but price discovery happens largely through computers. This is what the floor looks like today: Jason Meshnick In today's Market Recon piece over on TheStreet Pro, Stephen "Sarge" Guilfoyle discusses the trading action from Friday and Monday, and tells us that both Friday and Monday were overshoots from where the market should have traded. He says: "On Monday, U.S. equity markets absolutely roared back from a harsh selloff on Friday. On Friday, the algorithms that run price discovery in 2025 sold stocks en masse because of a recessionary looking labor report that was really three consecutive recessionary-looking labor reports at once. On Monday, those same algorithms bought the market hand over fist because now the Fed will likely have to cut short-term interest rates in six weeks." He goes on to say that this game of "Chutes and Ladders" is occurring because we've removed humans from the art of price discovery and replaced them with algorithms. While the market is much cheaper to run (spreads are down), markets are less efficient. In other words, day-to-day volatility might be lower, but reaction to news is much harsher. I couldn't agree more. Sarge also tells us that Wall Street strategists have turned bearish. They see a lethal combination of softening economic data and sky-high valuations. Perhaps "lethal" is a strong word. More accurately, they see a dip on the horizon that they feel will be worth buying. But the reason why I'm quoting Sarge so much today is that he more succinctly than anybody has listed the four reasons that valuations are high and deserve to be. Lower taxesLess regulationExpected lower interest ratesIncreased productivity (on a per-employee basis) driven by artificial intelligence. It all comes down to potential corporate growth and reduced expenses. Demand for workers probably will drop, however, which could be a net negative for economic growth. How is the stock market looking this morning? Slightly up. S&P 500 futures are higher by 0.12%, while Nasdaq futures are up 0.27%. ThinkOrSwim It's still earnings season and several major companies have reported this morning. TipRanks After market close, we await reports from AMD, Super Micro Computer, and others, including EV makers Rivian and Lucid. TipRanks Check back throughout the day! The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store